CART-19

BIOLOGICAL11 trials

Sponsors

University of Pennsylvania, Beijing Sanwater Biological Technology Co., Ltd., Fujian Medical University, Henan Cancer Hospital, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Conditions

Acute Lymphoblastic LeukemiaAcute Lymphocytic LeukemiaAcute Myeloid LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Patients Who Have Relapsed or Refractory CLL (3rd Line) or SLLB Cell LeukemiaB Cell LymphomaB-cell Adult Acute Lymphoblastic Leukemia

Phase 1

CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy

CompletedNCT01029366

University of PennsylvaniaAdult Acute Lymphoblastic Leukemia in Remission, B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia +20

Start: 2010-03-17End: 2016-05-31Updated: 2023-06-22

Allo CART-19 Protocol

TerminatedNCT01551043

University of PennsylvaniaAcute Lymphocytic Leukemia

Start: 2010-09-30End: 2016-06-30Updated: 2020-07-09

Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma

CompletedNCT01626495

University of PennsylvaniaB Cell Leukemia, B Cell Lymphoma

Start: 2011-08-17End: 2019-07-11Updated: 2020-03-23

Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia

Beijing Sanwater Biological Technology Co., Ltd.Acute Lymphoblastic Leukemia

Start: 2016-05-31Target: 20Updated: 2016-10-14

The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma

Henan Cancer HospitalB Cell Lymphoma

Start: 2016-08-31End: 2019-07-31Target: 30Updated: 2017-04-05

CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdAcute Myeloid Leukemia

Start: 2017-10-18End: 2025-12-31Target: 15Updated: 2023-11-29

CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma

RecruitingNCT06101381

University of Sao PauloLeukemia, Acute Lymphoblastic, Lymphoma, Non-Hodgkin

Start: 2024-03-21End: 2028-12-31Target: 81Updated: 2024-12-09

Phase 2

Dose Optimization Trial of CD19 Redirected Autologous T Cells

CompletedNCT01747486

University of PennsylvaniaAdult Patients Who Have Relapsed or Refractory CLL (3rd Line) or SLL

Start: 2013-01-02End: 2018-04-06Updated: 2023-06-22

Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia

CompletedNCT02030847

University of PennsylvaniaPatients With B Cell ALL, Relapsed or Refractory, With no Available Curative Treatment Options

Start: 2014-02-27End: 2018-04-26Updated: 2023-06-22

Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas

CompletedNCT02030834

University of PennsylvaniaNon-Hodgkins Lymphoma (NHL) Patients, With CD19+B Cell Lymphomas

Start: 2014-02-05End: 2020-09-01Updated: 2023-06-22

CART-19 Cells For MRD Positive CD19+ ALL

Fujian Medical UniversityAcute Lymphoblastic Leukemia

Start: 2016-11-30End: 2020-12-31Target: 20Updated: 2017-01-23

Related Papers

Decade-long persistence of CD19 CAR T cells in B cell lymphomas

Nature Medicine2026-08-10

Type II interferon-driven crosstalk between effector memory CART and myeloid cells is associated with CART19 resistance in relapsed refractory large B-cell lymphomas

Blood2025-11-03

A newly identified role for IL-5 in regulating CART-associated toxicity and efficacy

Blood2025-11-03

CD19 CAR-T in relapsed t(8;21) AML: a single-center prospective phase II clinical trial.

2025-05-0611 citations

Ketogenic Diet Enhances CAR T Cell Antitumor Function Via β-Hydroxybutyrate

Blood2024-11-057 citations

Unleashing the Power of CD19 CAR-T in Relapsed AML: Findings from a Prospective Single-Center Clinical Trial

Blood2024-11-054 citations

BTK Inhibition Prevents the Induction of Myeloid-Derived Suppressor Cells in Malignancy and Improves CART Function

Blood2024-11-052 citations

Serum-Based Proteomic Analysis of Cytokine Release Syndrome in Pediatric AML Patients Receiving CART123

Blood2024-11-051 citations

Curing CLL: Long-Term Outcomes of Chronic Lymphocytic Leukemia Patients with at Least One Year of Response to CART-19 Therapy

Blood2024-11-051 citations

<i>Overcoming the Lack of CD2:CD58 Costimulation in Chimeric Antigen Receptor T-Cell Immunotherapies</i>

Blood2024-11-05

Abstract B051: Marrow and peripheral blood cytokine architecture differences between pediatric patients receiving CD19- and CD22-directed CART

Cancer Research2024-09-05

Long Term Durable Responses in Relapsed/Refractory (r/r) ALL, DLBCL, and FL Patients Treated with Tisagenlecleucel and Its Association with Persistence of CAR T-Cells

Blood2023-11-024 citations

Modulation of the Btla-HVEM Axis to Enhance CAR T Cell Immunotherapy Against Cancer

Blood2023-11-022 citations

IL-10 Levels Differentially Regulate IFNg Signaling of CART19 and CART22

Blood2023-11-02

229 Large-scale omics profiling reveals type-2 functionality sustaining 8-year leukemia remission following CAR T cell therapy

Regular and Young Investigator Award Abstracts2023-10-31

Overcoming CD19-Negative Relapses in Patients with B-Cell Lymphomas Treated with Tisagenlecleucel

Blood2022-11-156 citations

572 Gut microbiota tuning promotes tumor-associated antigen cross-presentation and enhances CAR T antitumor effects

Regular and Young Investigator Award Abstracts2022-11-012 citations

Impact of socioeconomic status on survival after CD19 CART therapy.

Journal of Clinical Oncology2022-06-01

Immune Checkpoints are Important Therapeutic Targets in Cancer Immunotherapy

Cancer Science & Research2021-12-30

Outcomes after Reinfusion of CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Blood2021-11-0518 citations

36 more papers not shown